IL-1HY1: A Promising Drug Target and Biomarker for Diseases (G26525)

Target Name: IL36RN

NCBI ID: G26525

IL36RN

IL-1HY1: A Promising Drug Target and Biomarker for Diseases

IL36RN (IL-1HY1) is a protein that is expressed in a variety of tissues throughout the body, including the lungs, heart, kidneys, and gastrointestinal tract. It is a member of the Interleukin-1 family, which includes several different proteins that play important roles in immune and inflammatory responses.

IL-1HY1 is a cytokine, which means it is a protein that is released by cells in response to the presence of certain hormones or other signaling molecules. It is involved in the regulation of a wide range of physiological processes in the body, including immunity responses, inflammation, and cell growth and differentiation.

One of the things that makes IL-1HY1 an attractive drug target is its ability to interact with several different signaling pathways. For example, it can interact with the TGF-β pathway, which is involved in cell growth and differentiation, as well as the NF-kappa-B pathway, which is involved in inflammation and immune responses. This means that IL-1HY1 can be targeted by drugs that work by inhibiting these pathways, which could lead to a range of potential therapeutic benefits.

Another reason why IL-1HY1 is a promising drug target is its role in the development of certain diseases. For example, studies have shown that high levels of IL-1HY1 are associated with the development of a number of diseases, including heart disease, diabetes , and cancer. This suggests that targeting IL-1HY1 could be a way to treat these diseases.

In addition to its potential therapeutic benefits, IL-1HY1 is also a valuable biomarker for several different types of cancer. For example, studies have shown that high levels of IL-1HY1 are often associated with the development of certain types of cancer, such as breast cancer and colorectal cancer. This suggests that IL-1HY1 could be a useful diagnostic marker for these cancers, as well as a target for cancer therapies.

Overall, IL-1HY1 is a protein that has the potential to be a drug target or biomarker for a wide range of diseases. Its ability to interact with multiple signaling pathways and its association with the development of certain diseases make it an attractive target for researchers and clinicians. Further research is needed to fully understand the role of IL-1HY1 in these processes and to develop effective treatments.

Protein Name: Interleukin 36 Receptor Antagonist

Functions: Inhibits the activity of interleukin-36 (IL36A,IL36B and IL36G) by binding to receptor IL1RL2 and preventing its association with the coreceptor IL1RAP for signaling. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor. Proposed to play a role in skin inflammation. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus. May activate an anti-inflammatory signaling pathway by recruiting SIGIRR

The "IL36RN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL36RN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets